BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
| Revenue (TTM) | $8.60M |
| Gross Profit (TTM) | $-65.37M |
| EBITDA | $-120.26M |
| Operating Margin | -12554.00% |
| Return on Equity | -34.60% |
| Return on Assets | -22.40% |
| Revenue/Share (TTM) | $0.20 |
| Book Value | $7.54 |
| Price-to-Book | 0.68 |
| Price-to-Sales (TTM) | 28.50 |
| EV/Revenue | 0.917 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -85.50% |
| Shares Outstanding | $45.90M |
| Float | $39.24M |
| % Insiders | 2.36% |
| % Institutions | 91.40% |
Volatility is currently expanding
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIOA and any ticker you trade — then tracks every position and per-strategy win rate.
